Drug General Information
Drug ID	D06ABW
Former ID	DNC011356
Drug Name	CLIOQUINOL
Drug Type	Small molecular drug
Indication	Discovery agent		Withdrawn from market	[522766]
Structure		Download 2D MOL 3D MOL
Formula	C9H5ClINO
Canonical SMILES	C1=CC2=C(C(=C(C=C2Cl)I)O)N=C1
InChI	1S/C9H5ClINO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H
InChIKey	QCDFBFJGMNKBDO-UHFFFAOYSA-N
CAS Number	CAS 130-26-7
PubChem Compound ID	2788
SuperDrug ATC ID	D08AH30; D09AA10; G01AC02; P01AA02; S02AA05
Target and Pathway
Target(s)	Carbonic anhydrase	Target Info	Inhibitor	[529489]
	Kappa-type opioid receptor	Target Info	Inhibitor	[531262]
KEGG Pathway	Neuroactive ligand-receptor interaction
PANTHER Pathway	Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
	Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
	Opioid prodynorphin pathway
Reactome	Peptide ligand-binding receptors
	G alpha (i) signalling events
WikiPathways	GPCRs, Class A Rhodopsin-like
	Peptide GPCRs
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 522766	ClinicalTrials.gov (NCT00963495) Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy. U.S. National Institutes of Health.
Ref 529489	Bioorg Med Chem Lett. 2008 Jun 15;18(12):3593-6. Epub 2008 May 4.Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols.
Ref 531262	Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. Epub 2010 Oct 21.In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.